Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis

Rasha Khatib,1 Stephanie Ross,2 Sean Alexander Kennedy,2 Ivan D. Florez,2,3 Thomas L. Ortel,4 Robby Nieuwlaat,2 Ignacio Neumann,2 Daniel M. Witt,5 Sam Schulman,6,7 Veena Manja,8 Rebecca Beyth,9,10 Nathan P. Clark,11 Wojtek Wiercioch,2 Holger J. Schünemann,2,6 and Yuqing Zhang2,12
1Advocate Research Institute, Advocate Health Care, Downers Grove, IL; 2Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada; 3Department of Pediatrics, University of Antioquia, Medellin, Colombia; 4Division of Hematology, Medicine and Pathology, Duke University Medical Center, Durham, NC; 5Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT; 6Department of Medicine, McMaster University, Hamilton, ON, Canada; 7Department of Obstetrics and Gynecology, The First I. M. Sechenov Moscow State Medical University, Moscow, Russia; 8Department of Surgery, University of California Davis, Sacramento, CA; 9Division of General Internal Medicine, Department of Medicine, University of Florida, Gainesville, FL; 10Malcom Randall Veterans Affairs Medical Center, Gainesville, FL; 11Clinical Pharmacy Anticoagulation Service, Kaiser Permanente Colorado, Aurora, CO; and 12Guang’anmen Hospital, China Academy of Chinese Medical Science, Xicheng District, Beijing, China

Increasing evidence supports the safety and effectiveness of managing low-risk deep vein thrombosis (DVT) or pulmonary embolism (PE) in outpatient settings. We performed a systematic review to assess safety and effectiveness of managing patients with DVT or PE at home compared with the hospital. Medline, Embase, and Cochrane databases were searched up to July 2019 for relevant randomized clinical trials (RCTs), and prospective cohort studies. Two investigators independently screened titles and abstracts of identified citations and extracted data from relevant full-text papers. Risk ratios (RRs) were calculated, and certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE). Seven RCTs (1922 patients) were included in meta-analyses on managing patients with DVT. Pooled estimates indicated decreased risk of PE (RR = 0.64; 95% confidence interval [CI], 0.44-0.93) and recurrent DVT (RR = 0.61; 95% CI, 0.42-0.90) for home management, both with moderate certainty of the evidence. Reductions in mortality and major bleeding were not significant, both with low certainty of the evidence. Two RCTs (445 patients) were included in meta-analyses on home management of low-risk patients with PE. Pooled estimates indicated no significant difference in all-cause mortality, recurrent PE, and major bleeding, all with low certainty of the evidence. Results of pooled estimates from 3 prospective cohort studies (234 patients) on home management of PE showed similar results. Our findings indicate that low-risk DVT patients had similar or lower risk of patient-important outcomes with home treatment compared with hospital treatment. In patients with low-risk PE, there was important uncertainty about a difference between home and hospital treatment.

Introduction

Venous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE). It is the third most common cardiovascular disorder and affects 2% to 5% of the population during their lifetimes.1,2 The goal of therapy for VTE is to prevent the extension of thrombus and relieve symptoms in the short-term while preventing recurrent events in the long-term. Heparin has been the anticoagulant of choice for treatment of acute VTE.3 More recently, direct oral anticoagulants (DOACs) such as apixaban...
and rivaroxaban have eliminated the need for low-weight-molecular heparin (LMWH) in acute VTE treatment.

VTE has been traditionally managed in the hospital. However, evidence from several randomized controlled trials (RCTs) as early as the 1990s have indicated that outpatient management may be safe and effective.4,5 These results prompted updates in clinical practice guidelines.6,7 The introduction of DOACs for VTE treatment removes the need for injectable coagulants and close laboratory anticoagulant monitoring, making home management even more possible.8 Despite these recommendations and the increasing evidence that home treatment is safe and efficacious, many patients, even those with low risk of complications, are admitted for hospital management.9,10

In this report, we provide a comprehensive and systematic review of the literature and elect to incorporate prospective observational studies in addition to RCTs to determine whether any evidence to avoid home management of DVT or PE exists, particularly among those with "low-risk PE."

Unlike previous reports, we systematically review the evidence for home management of DVT and PE in 1 report, using standardized inclusion criteria, pooled analysis methods, and assessment of the evidence methods for DVT and PE. We aim to answer the following 2 questions for the American Society of Hematology (ASH) Clinical Practice Guidelines on Treatment of VTE:

1. Should home treatment vs hospital treatment be used for patients with uncomplicated DVT?
2. Should home treatment vs hospital treatment be used for patients with PE and low risk of complications?

Methods

This systematic review was performed as part of the ASH Guidelines on Treatment of VTE, developed in partnership with the McMaster University’s Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre. Review and meta-analysis methodology followed the Cochrane Handbook11 with reporting according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.12

Search strategy

To develop each search strategy, we identified previously published systematic reviews on outpatient management of DVT and PE using Epistemonikos (www.epistemonikos.org). We identified and updated 2 Cochrane systematic reviews, 1 addressing DVT and the other addressing PE.8,13 The number of studies addressing PE was expected to be small and therefore the ASH VTE treatment panel decided to search for prospective observational studies in addition to RCTs for the management of PE. For each search, Medline (1996 to week 3 of July 2019), Embase (1974 to week 3 of July 2019), and the Cochrane Central Register of Controlled Trials (until week 3 of July 2019) were searched. Predefined search terms included “pulmonary embolism” or “pulmonary thromboembolism” or “deep vein thrombosis” and “home treatment” or “outpatient treatment” or “ambulant treatment” or “early discharge.” The searches were restricted to studies of human subjects but not restricted by language. The Medline search strategies are provided in supplemental Material 1. Additionally, the reference lists of relevant studies and reviews were reviewed, and clinical experts in the field of VTE and anticoagulation treatment were consulted for additional references.

Study selection

Two reviewers independently screened titles, abstracts, and the full text of relevant articles based on prespecified inclusion and exclusion criteria. Disagreements were resolved by consensus and by a third reviewer when needed. RCTs and prospective cohort studies were included if they satisfied the following characteristics: included adults ages 18 years and older diagnosed with verified symptomatic uncomplicated DVT or low-risk PE (low-risk PE was classified by any validated or unvalidated measurement tool that aimed to classify mortality risk rate related to PE such as the Pulmonary Embolism Severity Index [PESI])14, evaluated the safety and efficacy of home treatment of DVT or PE, or a short hospital admission for up to 72 hours after diagnosis and continued treatment at home past the 72 hours, and used hospital treatment of DVT or PE as the comparison group. Inclusion was not restricted by type of anticoagulant (eg, DOAC or LMWH).

The following outcomes were prioritized as critical for clinical decision-making by the ASH guideline panel: all-cause mortality, PE or recurrent PE, which was considered present if documented objectively, or in case of death in which PE could not be confidently ruled out as a contributing cause, DVT or recurrent DVT, which was considered present if documented objectively. The objective criteria for DVT were either a venous segment of thrombus on ultrasonography or a new intraluminal filling defect on contrast venography. Major bleeding during the first 3 months after the initial DVT or PE diagnosis was defined using the International Society on Thrombosis and Haemostasis (ISTH) criteria.15

To answer question 1 regarding patients with uncomplicated DVT, we included RCTs only. To answer question 2 on patients with PE and low risk of complications, we included RCTs and prospective cohort studies. This decision to include prospective cohort studies was made by ASH panel members given the small number of RCTs identified.

Data abstraction and analysis

One reviewer extracted data from each eligible study using a pretested data abstraction form, and data were checked by another reviewer to assess accuracy. Disagreements were resolved by discussion, and by a third reviewer when needed. The data collected included patient characteristics including age and sex, intervention and control group details, mean hospital length of stay, and duration of follow up. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated by pooling the results from RCTs using the Mantel-Haenszel method and the random effects model. Heterogeneity was assessed using the I² index and was deemed as moderate to high with an I² over 50%.11 Data were analyzed using RevMan 5.3. Two reviewers evaluated the certainty of the evidence for each outcome using the GRADE approach.16 The certainty of the evidence was assessed as high, moderate, low, or very low and summarized in a GRADE Evidence Profile.16

Risk of bias

Information on risk of bias was collected and assessed for each outcome in each included study using the Cochrane risk of bias tool.
for RCTs. The Cochrane risk of bias tool was adapted for prospective observational studies. The following items were included: adequate assessment of exposure, clear selection for home treatment, adequate study population, adequacy of follow-up and assessment of outcome. Assessment of exposure was considered adequate when the index PE was diagnosed with 1 of the following imaging techniques: pulmonary angiography, computed tomography angiography, high probability ventilation-perfusion (V/Q) scan or intermediate probability V/Q scan combined with a positive compression ultrasonography for DVT. An unambiguous selection for home treatment was present if predefined exclusion criteria were used to select whether a patient could be treated as an outpatient. A study population was considered adequate if it consisted of consecutive patients or included a random sample of all potentially eligible patients. Complete follow-up was required in at least 80% of patients for follow-up to be considered adequate. Assessment of outcome was adequate when objective criteria were used, comparable to the international criteria for assessing recurrent VTE or major bleeding.

Results

Search results

Home vs hospital treatment of uncomplicated DVT. A total of 452 unique citations were identified from the electronic database search and from other sources. Based on title and abstract screening, 438 citations were excluded. An additional 6 citations were excluded based on full-text screening. A total of 7 studies were included in our systematic review and meta-analysis. Supplemental Material 2 presents the PRISMA diagram.

Home vs hospital treatment of low-risk PE. A total of 288 and 1435 unique citations were identified from the electronic database searches for RCTs and prospective, observational studies, respectively. Based on title and abstract screening, 271 and 1411 citations were excluded from each search. An additional 15 and 24 citations were excluded based on full-text screening. A total of 2 RCTs and 3 prospective observational studies were included in our systematic review and meta-analysis. Supplemental Material 2 presents the PRISMA diagram.

Study characteristics

Home vs hospital treatment of uncomplicated DVT. A total of 7 RCTs (1922 patients) investigated hospital vs home treatment of patients with uncomplicated DVT (Table 1). Five studies were conducted in France, Greece, Canada, Brazil, and Spain. The remaining 2 studies were conducted in multiple countries including Australia, New Zealand, Poland, South Africa, The Netherlands, France, and Italy. One of the 7 studies did not provide details on treatment. The remaining 6 reported treating patients in the intervention group with subcutaneous injections of LMWH, 3 of which stopped LMWH and continued with warfarin at home. One of the 6 studies reported treating patients in the control group with subcutaneous injection of LMWH in the hospital followed by oral anticoagulants. The remaining 5 studies reported treating patients with unfractionated heparin (UFH). None of the studies reported using DOACs. Length of hospital stay was reported in 4 studies and ranged between 1 and 3 days for the home care group and between 6.5 and 9.6 days for the control group. Duration of follow-up ranged from 10 days to 12 months.

Home vs hospital treatment of low-risk PE. We included 2 RCTs (453 patients) and 3 prospective observational studies (234 patients) (Table 2). Studies were conducted in United States, Italy, Spain, and Switzerland. One study was conducted in multiple countries including Switzerland, France, Belgium, and the United States. Assessment of low risk of death to determine eligibility for home treatment varied by study. PESI was used in 1 RCT and Hestia criteria were used in the other RCT. One of the prospective cohort studies used an unvalidated risk score and the remaining 2 studies did not report their methods. One of the studies included patients treated with DOACs, the remaining studies included LMWH and UFH with transition to vitamin K antagonist (VKA) therapy. Little information was reported on defining the intervention (home treatment). In the 2 RCTs home care patients were discharged from the emergency department within 24 hours. The prospective observational studies reported a mean length of hospital stay for home care patients of 3.1 hours in 1 study and 0 days in another. The third study did not report a hospital length of stay. Patients were followed up for 6 months in 1 study and for 3 months in the remaining 4 studies.

Risk of bias

Home vs hospital treatment of uncomplicated DVT. Among the 7 included RCTs, allocation was clearly concealed in 3 trials. In contrast, concealment was unclear in 3 studies and probably unsealed in 1. Outcome adjudicators were clearly blinded in the 2 largest RCTs and unclear in the remaining 5 RCTs. Missing data were significant in 1 small RCT only. A summary of risk of bias for each RCT and associated Forest plots are presented in Figure 1.

Home vs hospital treatment of low-risk PE. Among the 2 included RCTs, overall risk of bias was low as both studies adequately concealed allocation, blinded outcome adjudicators, and missing data were minimal. A summary of risk of bias for each RCT and associated forest plots are presented in Figure 2. Among the 3 prospective cohort studies, risk of bias was high due to lack of adjustment for possible confounders, subjective assessment of outcomes, and lack of information on loss to follow-up (supplemental Material 3).

Synthesis of results

Home vs hospital treatment of uncomplicated DVT.

ALL-CAUSE MORTALITY. One RCT (214 patients) assessed mortality at 10 days from randomization (short-term mortality). The study reported 0 events in both groups (Figure 1). The certainty of the evidence was low because of serious risk of bias and serious imprecision in the anticipated absolute effect (Table 3). Six studies (1708 patients) assessed long-term mortality, ranging between 3 months to 12 months from randomization. The pooled RR was 0.72 (95% CI, 0.45, 1.15) in favor of home management, and no heterogeneity was observed ($I^2 = 0$; Figure 1). The certainty of the evidence, based on the GRADE criteria, was assessed as low because of serious risk of bias, due to lack of allocation concealment and missing data.
Table 1. Characteristics of included studies comparing home vs hospital treatment of patients with uncomplicated DVT

| Author, y | Country | No. of patients | Intervention: home treatment | Control: hospital treatment | Mean hospital length of stay ± SD, d | Mean age ± SD, y | Known cancer, % | Female, % | Follow-up |
|-----------|---------|----------------|-----------------------------|-----------------------------|-----------------------------------|-----------------|------------------|------------|-----------|
| Koopman et al, 1996 | Netherlands, France, Italy, New Zealand, Australia | Home: 198 Hospital: 202 | LMWH at home when appropriate, oral anticoagulant treatment was initiated on the first day and continued for a total of 3 mo | UFH in hospital, oral anticoagulant treatment was initiated on the first day and continued for a total of 3 mo | Home: 2.7 Hospital: 8.1 | Hospital: 59 ± 17 Hospital: 62 ± 16 | Hospital: 18 Home: 17 | 49.3 | 6 mo |
| Levine et al, 1996 | Canada | Home: 253 Hospital: 247 | LMWH primarily at home, warfarin started on end of day 2 and continued for minimum 3 mo | UFH in hospital, warfarin started on end of day 2 and continued for minimum 3 mo | Home: 1.1 ± 2.9 Hospital: 6.5 ± 3.4 | Hospital: 57 ± 17 Hospital: 59 ± 15 | Hospital: 19 Home: 23 | 39.8 | 3 mo |
| Boccalon et al, 2000 | France | Home: 99 Hospital: 102 | Injection of LMWH followed by OA for 6 mo at home; compression stockings | Injection of LMWH followed by OA for 6 mo initial in hospital for 10 ± 2 d, then at home; compression stockings | Home: 1.0 ± 1.6 Hospital: 8.6 ± 3.6 | 63.8 ± 14.1 | Not reported 43.8 | 6 mo |
| Ramacciotti et al, 2004 | Brazil | Home: 97 Hospital: 104 | LMWH injection for 5-10 d, given at home or in hospital; warfarin for at least 3 mo starting at day 1 or 2 of treatment | UFH for 5 10 d in hospital; warfarin for at least 3 mo starting at day 1 or 2 of treatment | Home: 3.0 ± 3.0 Hospital: 7 ± 3 | Hospital: 44 ± 18 Hospital: 46 ± 19 | Not reported 65.7 | 6 mo |
| Chong et al, 2005 | Australia, New Zealand, Poland, South Africa | Home: 150 Hospital: 148 | Injection of LMWH for a minimum of 5 d plus warfarin for 3 mo | UFH for a minimum of 5 d, plus warfarin started on day 1 of treatment, for 3 mo | Not reported | Hospital: 54.9 ± 17.7 Hospital: 55.8 ± 16.8 | Not reported 47.7 | 24 wk |
| Daskalopoulos et al, 2005 | Greece | Home: 53 Hospital: 55 | Injection of LMWH for 6 mo | UFH 5 to 7 d; oral anticoagulant was commenced on the third day following UFH therapy for 6 mo | Not reported; patients allocated to home underwent no hospitalisation | Median (range) | Hospital: 6 59.8 | 12 mo |
| Romera-Villegas et al, 2008 | Spain | Home: 111 Hospital: 103 | Received care at home with early walking and compression stockings | Hospitalized and received 5 d of bed rest | Not reported | 64.2 | Not reported 46.1 | 10 d |

OA, oral anticoagulation; SD, standard deviation; UFH, unfractionated heparin.
### Table 2. Characteristics of included studies comparing home vs hospital treatment of patients with low-risk PE

| Author, y | Country | Study design | No. of patients | Intervention: home treatment | Control: hospital treatment | Mean hospital length of stay | Mean age ± SD, y | Female, % | Known cancer, % | Duration of follow-up, mo | How was risk of PE complications determined? |
|-----------|---------|--------------|-----------------|-----------------------------|-----------------------------|-----------------------------|-----------------|-----------|------------------|--------------------------|-----------------------------------------------|
| Beer et al,24 2003 | Switzerland | Cohort | Home: 43, Hospital: 62 | LMWH for 5-10 d; oral anticoagulation was continued for 6-12 mo; treated at home | LMWH for 5-10 d; oral anticoagulation was continued for 6-12 mo; treated in hospital | Not reported | Median (range): 69 (18-96) | Not reported | Not reported | 3 | Unvalidated prediction tool |
| Siragusa et al,25 2005* | Italy | Cohort | Home: 36, Hospital: 32 | LMWH followed by warfarin or with LMWH alone; treated at home | LMWH followed by warfarin or with LMWH alone; treated in hospital | Home: 3.1 h | Not reported for PE sample | Not reported for PE sample | Not reported for PE sample | 6 | Poor clinical conditions related to concomitant medical disorders, illness that independently required hospitalization, poor compliance, high risk of bleeding or active bleeding, renal insufficiency, acute anemia, pain requiring parenteral narcotics |
| Rodriguez-Cerrillo et al,26 2009† | Spain | Cohort | Home: 30, Hospital: 31 | LMWH followed by warfarin or with LMWH alone; treated at home | LMWH followed by warfarin or with LMWH alone; treated in hospital | Home: 0 d | Median (range): Home: 66.8 (27-91), Hospital: 66.7 (31-90) | Home: 30 | Not reported | 3 | Massive PE, hemodynamic instability, oxygen saturation lower than 92% on room air, heart failure, hemoptysis, arrhythmia, contraindication for LMWH |
| Aujesky et al,22 2011 | Switzerland, France, Belgium, US | RCT | Home: 171, Hospital: 168 | LMWH and VKA; admitted to hospital | LMWH and VKA; admitted to hospital | All patients discharged from ED within 24 h of randomization | Home: 47, Hospital: 49 | 50.9 | Home: 1, Hospital: 2 | 3 | PESI |
| Frank Peacock et al,23 2018 | US | RCT | Home: 51, Hospital: 63 | Rivaroxaban for 90 d Standard-of-care including bridging therapy or DOAC; admitted to hospital | All patients discharged from ED within 24 h | 48.26 ± 15.5 | 51.8 | Home: 6, Hospital: 6 | 3 | Hestia criteria |

*Siragusa et al25 included patients with PE and DVT and included patients with cancer only.
†Rodriguez-Cerrillo et al26 were randomized to hospital or home hospital. Home hospital patients were managed in their own homes.
### All-cause mortality- short term (follow-up: 10 days)

| Study or Subgroup | Home | Hospital |
|-------------------|------|----------|
| Events            | Total| Events   | Total| Weight|
| Romera-Villegas 2008 | 0   | 111      | 0   | 103    |

Total (95% CI) 111 103 Not estimable

Heterogeneity: Not applicable

Test for overall effect: Not applicable

### All-cause mortality- long term (follow-up: 3 months to 12 months)

| Study or Subgroup | Home | Hospital |
|-------------------|------|----------|
| Events            | Total| Events   | Total| Weight|
| Boccalon 2000     | 0   | 99       | 2   | 102   |
| Chong 2005        | 2   | 150      | 2   | 148   |
| Daskalopoulos 2005 | 1 | 55       | 2   | 53    |
| Koopman 1996      | 14  | 202      | 16  | 198   |
| Levine 1996       | 11  | 247      | 17  | 253   |
| Ramacciotti 2004  | 104 | 0        | 97  |        |

Romera-Villegas 2008 39 12 Not estimable

Total (95% CI) 857 851 100.0% 0.72 [0.45, 1.15]

Heterogeneity: $\chi^2 = 4.01, df = 5 (P = 0.55); I^2 = 0$

Test for overall effect: $Z = 1.37 (P = 0.17)$

### Deep Venous Thrombosis (follow-up: 3 months to 12 months)

| Study or Subgroup | Home | Hospital |
|-------------------|------|----------|
| Events            | Total| Events   | Total| Weight|
| Boccalon 2000     | 0   | 99       | 2   | 102   |
| Chong 2005        | 4   | 150      | 14  | 148   |
| Daskalopoulos 2005 | 5 | 55       | 6   | 53    |
| Koopman 1996      | 14  | 202      | 17  | 198   |
| Levine 1996       | 13  | 247      | 17  | 253   |
| Ramacciotti 2004  | 2   | 104      | 7   | 97    |
| Romera-Villegas 2008 | 3 | 111      | 2   | 103   |

Boccalon 2000 39 12 Not estimable

Total (95% CI) 857 851 100.0% 0.61 [0.42, 0.90]

Heterogeneity: $\chi^2 = 5.12, df = 6 (P = 0.53); I^2 = 0$

Test for overall effect: $Z = 2.35 (P = 0.02)$

### Pulmonary Embolism (follow-up: 10 days to 12 months)

| Study or Subgroup | Home | Hospital |
|-------------------|------|----------|
| Events            | Total| Events   | Total| Weight|
| Boccalon 2000     | 1   | 99       | 2   | 102   |
| Chong 2005        | 4   | 150      | 14  | 148   |
| Daskalopoulos 2005 | 5 | 55       | 6   | 53    |
| Koopman 1996      | 14  | 202      | 17  | 198   |
| Levine 1996       | 13  | 247      | 17  | 253   |
| Ramacciotti 2004  | 2   | 104      | 7   | 97    |
| Romera-Villegas 2008 | 3 | 111      | 2   | 103   |

Boccalon 2000 28 39 Not estimable

Total (95% CI) 857 851 100.0% 0.72 [0.45, 1.15]

Heterogeneity: $\chi^2 = 5.01, df = 5 (P = 0.55); I^2 = 0$

Test for overall effect: $Z = 2.35 (P = 0.02)$

### Major bleeding (follow-up: 10 days to 12 months)

| Study or Subgroup | Home | Hospital |
|-------------------|------|----------|
| Events            | Total| Events   | Total| Weight|
| Boccalon 2000     | 2   | 99       | 2   | 102   |
| Chong 2005        | 0   | 150      | 3   | 148   |
| Daskalopoulos 2005 | 2 | 55       | 4   | 53    |
| Koopman 1996      | 1   | 202      | 4   | 198   |
| Levine 1996       | 5   | 247      | 3   | 253   |
| Ramacciotti 2004  | 2   | 104      | 2   | 97    |
| Romera-Villegas 2008 | 0 | 111      | 0   | 103   |

Boccalon 2000 12 18 Not estimable

Total (95% CI) 968 954 100.0% 0.67 [0.33, 1.36]

Heterogeneity: $\chi^2 = 4.01, df = 5 (P = 0.55); I^2 = 0$

Test for overall effect: $Z = 1.11 (P = 0.27)$

---

**Figure 1. Treatment of DVT at home vs in hospital: RCTs.** Risk of bias legend: (A) random sequence generation (selection bias); (B) allocation concealment (selection bias); (C) blinding of participants and personnel (performance bias); (D) blinding of outcome assessment (detection bias); (E) incomplete outcome data (attrition bias); (F) selective reporting (reporting bias); and (G) other bias.
and serious impression in the anticipated absolute effect (Table 3).4,5,17-21

PE. Seven RCTs (1922 patients) assessed PE outcomes between 2.1 to 10 days from randomization.4,5,17-21 The pooled RR was 0.64 (95% CI, 0.44, 0.93) in favor of home treatment and no heterogeneity was observed (I2 = 0; Figure 1).4,5,17-21 The certainty of the evidence was moderate because of serious risk of bias in included studies, due to allocation concealment, unclear blinding of outcome adjudicators, and missing data (Table 3).4,5,17-21

RECURRENT DVT. Six studies (1708 patients) assessed recurrent DVT of the upper leg outcomes between 2.1 to 10 days from randomization.4,5,17-20 The pooled RR was 0.61 (95% CI, 0.42, 0.90) in favor of home treatment and no heterogeneity was observed (I2 = 0; Figure 1).4,5,17-20 The certainty of the evidence was moderate because of serious risk of bias in included studies, due to allocation concealment, unclear blinding of outcome adjudicators, and missing data (Table 3).4,5,17-21

### Table 2. Treatment of PE at home vs in hospital: RCTs

| Study or Subgroup | Risk Ratio | Risk Ratio | Risk of Bias |
|------------------|-----------|-----------|--------------|
|                  | Hospital treatment | Home treatment | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI | A | B | C | D | E | F | G |
| Aujesky 2011     | 0.98 [0.06, 15.58] | 1.000 | Not estimable | Not estimable |
| Peacock 2018     | 2.95 [0.12, 71.85] | 2.95 [0.12, 71.85] | 2.95 [0.12, 71.85] | 2.95 [0.12, 71.85] |
| Total (95% CI)   | 1.000 | 1.000 | 1.000 | 1.000 |

**Figure 2.** Treatment of PE at home vs in hospital: RCTs. Risk of bias legend: (A) random sequence generation (selection bias); (B) allocation concealment (selection bias); (C) blinding of participants and personnel (performance bias); (D) blinding of outcome assessment (detection bias); (E) incomplete outcome data (attrition bias); (F) selective reporting (reporting bias); and (G) other bias.
Table 3. GRADE summary: should we treat at home rather than admit to the hospital patients with DVT?

| No. of participants (studies) follow-up | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall certainty of evidence | Study event rates, n/N (%) | Relative effect (95% CI) | Anticipated absolute effects |
|----------------------------------------|-------------|---------------|--------------|-------------|-----------------|------------------------------|----------------------------|-------------------------|-----------------------------|
| **All-cause mortality, short-term; follow-up: 10 d** | | | | | | | | | |
| 214 (1 RCT)²¹ | Serious* a | Not serious | Not serious | Serious† | None | Low | 0/103 (0.0) | 0/111 (0.0) | Not estimable | 0 per 1000 |
| **Long-term mortality; follow-up: range, 3-12 mo** | | | | | | | | | |
| 1708 (6 RCTs)⁴,¹⁵,¹⁷-²⁰ | Serious# | Not serious | Not serious§ | Serious† | None | Low | 39/851 (4.6) | 28/857 (3.3) | RR 0.72 (0.45-1.15) | • Study population: 46 per 1000 |
| | | | | | | | 65/954 (6.8) | 42/968 (4.3) | RR 0.64 (0.44-0.93) | • Study population: 25 fewer per 1000 (from 37 fewer to 10 more) |
| **PE, moderate; follow-up: range, 10 d to 12 mo** | | | | | | | | | |
| 1922 (7 RCTs)⁴,¹⁵,¹⁷-²¹ | Serious# | Not serious | Not serious§ | Not serious | None | Moderate | 63/851 (7.4) | 39/857 (4.6) | RR 0.61 (0.42-0.90) | • Study population: 29 fewer per 1000 (from 43 fewer to 7 fewer) |
| **Proximal DVT in the upper leg, moderate; follow-up: range, 3-12 mo** | | | | | | | | | |
| 1708 (6 RCTs)⁴,¹⁵,¹⁷-²⁰ | Serious# | Not serious | Not serious§ | Not serious | None | Moderate | 63/851 (7.4) | 39/857 (4.6) | RR 0.61 (0.42-0.90) | • Study population: 29 fewer per 1000 (from 43 fewer to 7 fewer) |

*The allocation was probably un concealed in 1 with unspecified opaque envelope; participants and personnel, outcome assessors were probably not blinded.
†CI includes values suggesting substantial benefit and values suggesting substantial harm
‡Of 6 RCTs, the allocation was clearly concealed in 3 (unclear in 3); outcome adjudicators were clearly blinded in the 2 largest RCTs (unclear in remaining 4), and missing data were significant in 1 small RCT.
§Four RCTs had partial hospital treatment of some participants in the home group: Levine et al ⁷ (mean hospital stay 1.1 vs 6.5 days in home and hospital arms, respectively), Koopman et al ⁴ (2.7 vs 8.1 days), Boccalon et al ¹⁷ (1 vs 9.6 days), and Ramacciotti et al ¹⁸ (3 vs 7 days). Chong et al ¹⁹, Daskalopoulos et al ²⁰ and Remes-Villegas et al ²¹ did not report mean duration of hospital stay.
| The Registro Informatizado de la Enfermedad Tromboembólica (RIETE) registry data compared outcomes in consecutive outpatients with acute lower limb DVT according to initial treatment at home (n = 4456) or in the hospital (n = 9037). Among 9037 patients treated in the hospital, the 90-day all-cause mortality rate was 6.64%, recurrent DVT was 1.11%, symptomatic PE was 0.64%, major bleeding rate was 1.65%.
| Study event rates, n/N (%) | Summary of findings | Anticipated absolute effects |
|---------------------------|---------------------|-----------------------------|
| Relative effect (95% CI)  | Risk with hospital treatment | Risk difference with home treatment |
| RR 0.67 (0.33-1.36)      | 18/854 (1.9)        | 12/968 (1.2)                |

Table 3. (continued)

### Certainty assessment

| No. of participants (studies) follow-up | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall certainty of evidence |
|----------------------------------------|--------------|---------------|--------------|-------------|-----------------|-------------------------------|
| Major bleeding; follow-up: range 10 d to 12 mo |
| 1922 (7 RCTs)3,11,17-21                  | Serious†     | Not serious‡  | Not serious§ | Serious†     | None            | Low                           |

---

**Key findings**

Low to moderate certainty evidence suggested that there is no additional risk and a potential benefit, in managing uncomplicated DVT patients treated in hospital (90-d risk of recurrence of major bleeding): 17 per 1000|

---

**Discussion**

Two RCTs (445 patients) assessed major bleeding at 3 months. The RR was 0.33 (95% CI, 0.01, 7.87) in favor of home treatment (Figure 2). The certainty of the evidence was low because of very serious impression in the anticipated absolute effect (Table 4). Four RCTs had partial hospital treatment of some participants in the home group: Levine et al (mean hospital stay 1.1 vs 6.5 days in home and hospital arms, respectively), Koopman et al (2.7 vs 8.1 days), Boccalon et al (1 vs 9.6 days), and Ramacciotti et al (3 vs 7 days). Chong et al, Daskalopoulos et al, and Romera-Villegas et al did not report mean duration of hospital stay.

---

**GRADE criteria, was assessed as low because of serious risk of bias due to allocation concealment, unclear bias, and missing data.**
Table 4. GRADE summary: should we treat at home rather than admit to the hospital patients with PE and low risk of complications?

| No. of participants (studies) follow-up | Risk of bias | Inconsistency | Indirectness | Imprecision | Publication bias | Overall certainty of evidence | Study event rates, n/N (%) | Summary of findings | Anticipated absolute effects |
|----------------------------------------|--------------|---------------|--------------|-------------|-----------------|-----------------------------|---------------------------|-----------------------|------------------------|
|                                         |              |               |              |             |                 |                             |                           |                       |                        |
| Mortality short-term; follow-up: mean, 30 d |              |               |              |             |                 |                             |                           |                       |                        |
| 451 (2 RCTs)22,23 | Not serious | Not serious | Not serious | Very serious* | None | ☐☐☐ Low | 1/229 (0.4) 0/222 (0.0) | RR 0.33 (0.01-7.98) | Study population: 4 per 1000 | Low-risk PE patients treated in hospital (30-d risk of mortality): 2 fewer per 1000 (from 2 fewer to 16 more) |
| PE; follow-up: mean, 90 d |              |               |              |             |                 |                             |                           |                       |                        |
| 445 (2 RCTs)22,23 | Not serious | Not serious | Not serious | Very serious* | None | ☐☐☐ Low | 0/223 (0.0) 1/222 (0.5) | RR 0.98 (0.06-15.58) | Study population: 0 per 1000 | Low-risk PE patients treated in hospital (90-d risk of mortality): 7 fewer per 1000 (from 1 fewer to 64 more) |
| DVT; follow-up: mean, 90 d |              |               |              |             |                 |                             |                           |                       |                        |
| 445 (2 RCTs)22,23 | Not serious | Not serious | Not serious | Very serious* | None | ☐☐☐ Low | 0/223 (0.0) 0/222 (0.0) | Not estimable | Study population: 0 per 1000 | Low-risk PE patients treated in hospital (90-d risk of recurrence of DVT): 23 fewer per 1000 (from 11 fewer to 850 more) |

*Small number of events in included studies, also wide CI covers appreciable benefit and harm.
†A meta-analysis of 2 cohort studies and 2 RCTs including 329 PE patients treated as inpatients had recurrent VTE risk as 1.2% (95% CI, 0.16-8.14%). Within 383 PE patients treated as inpatients, the major bleeding risk was 1.0% (95% CI, 0.30-2.75%), the all-cause mortality was 0.74% (95% CI, 0.04-11.14).32
‡There is a high risk of bias because the adjustment for additional factors, assessment of outcomes, and adequacy of follow-up was not reported for most studies.
§There was a high degree of inconsistency among the pooled estimates. One of the trials consisted of patients who had active or palliative cancer and may have had a higher risk of dying as compared with the other patient populations included in the systematic review.
| Study event rates, n/N (%) | Summary of findings | Anticipated absolute effects |
|---------------------------|---------------------|-----------------------------|
| Relative effect (99% CI)  | Risk with hospital treatment | Risk difference with home treatment |
|                           | With hospital treatment | With home treatment |
|                           | RR (95% CI)           | RR (95% CI)                |

### Major bleeding; follow-up: mean, 90 d

| No. of participants (studies) follow-up | Risk of bias | Inconsistency | Indirectness | Imprecision | Overall certainty of evidence | Study population: 0 per 1000 | Study population: 0 fewer per 1000 |
|----------------------------------------|--------------|---------------|--------------|-------------|-------------------------------|-------------------------------|----------------------------------|
| 445 (2 RCTs)22,23                     | Not serious  | Not serious   | Not serious  | Very serious* | Low                           | 0/223 (0.0)                   | Low                             |
|                                        |              |               |              |              |                               | 3/222 (1.4)                  |                                 |
|                                        |              |               |              |              |                               | RR 6.88 (0.36-132.14)        |                                 |
|                                        |              |               |              |              |                               | 96 per 1000                   | 18 fewer per 1000 (from 56 fewer to 56 more) |
|                                        |              |               |              |              |                               | 0 per 1000                    | 0 fewer per 1000 |

*Small number of events in included studies, also wide CI covers appreciable benefit and harm.

†A meta-analysis of 2 cohort studies and 2 RCTs including 329 PE patients treated as inpatients had recurrent VTE risk as 1.2% (95% CI, 0.16-8.14%). Within 383 PE patients treated as inpatients, the major bleeding risk was 1.0% (95% CI, 0.39-2.75%), the all-cause mortality was 0.74% (95% CI, 0.04-11.14).32

‡There is a high risk of bias because the adjustment for additional factors, assessment of outcomes, and adequacy of follow-up was not reported for most studies.

§There was a high degree of inconsistency among the pooled estimates. One of the trials consisted of patients who had active or palliative cancer and may have had a higher risk of dying as compared with the other patient populations included in the systematic review.
implications for clinical practice

The report complements comprehensive evidence on the efficacy and safety of home management of DVT and PE and includes RCTs as well as observational studies. Our review did not identify any RCTs conducted past 2006 on management of DVT. At the time, LMWH during the transition to VKA therapy was the recommended approach. The need for subcutaneous injections and routine follow-up with LMWH also requires patients to be aware of their diet and the frequent use of risk stratification in clinical settings makes the implementation of outpatient management for patients with lower risk of complications more challenging.

In addition to better or similar efficacy and safety outcomes, home management of PE and DVT is cost saving. A matched case control study compared hospital and home treated over 6 months by rivaroxaban and compared costs of hospital treated patients (P < 0.001) and 56% lower for DVT patients (P = 0.003). Our review did not identify any RCTs conducted past 2006 on management of DVT. At the time, LMWH during the transition to VKA therapy was the recommended approach. The need for subcutaneous injections and routine follow-up with LMWH also requires patients to be aware of their diet and the

Figure 3. Treatment of PE at home vs in hospital: observational prospective studies. Siragusa et al. included PE and DVT patients, the meta-analysis presents outcomes for PE patients only.

Table 1. Major bleeding (follow-up 3 or 6 months)

| Study or Subgroup | Hospital Treatment | Risk Ratio | 95% Cl | Weight | Heterogeneity | M-H, Fixed, 95% Cl |
|-------------------|-------------------|-----------|--------|--------|--------------|-------------------|
| Siragusa 2005     | 103               | 1.10      | 0.86   | 100.0% | Not applicable | 1.10 [0.86, 1.40]  |
| Rodríguez-Cerrillo 2009 | 103   | 2.70      | 0.72   | 100.0% | Not applicable | 2.70 [0.72, 9.92]  |
| Beer 2003         | 109               | 1.10      | 0.81   | 100.0% | Not applicable | 1.10 [0.81, 1.50]  |

Table 2. All-cause mortality: long-term follow-up (3 to 6 months)

| Study or Subgroup | Hospital Treatment | Risk Ratio | 95% Cl | Weight | Heterogeneity | M-H, Fixed, 95% Cl |
|-------------------|-------------------|-----------|--------|--------|--------------|-------------------|
| Siragusa 2005     | 11                | 1.01      | 1.00   | 100.0% | Not applicable | 1.01 [1.00, 1.01]  |
| Rodríguez-Cerrillo 2009 | 12   | 1.01      | 1.00   | 100.0% | Not applicable | 1.01 [1.00, 1.01]  |
| Beer 2003         | 11                | 1.01      | 1.00   | 100.0% | Not applicable | 1.01 [1.00, 1.01]  |

In summary, observational studies continue to report in hospital management of DVT and PE. An analysis of 652,000 and 394,000 emergency room visits in the US for DVT and PE between 2006 and 2010 indicate that 52% of DVT patients and 90% of PE patients were managed in the hospital. A retrospective analysis of 639 patients with PE and DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among PE patients only.

The large number of hospital admission suggests that many patients at low risk of complications are being admitted. With low risk of complications more challenging.

In summary, observational studies continue to report in hospital management of DVT and PE. An analysis of 652,000 and 394,000 emergency room visits in the US for DVT and PE between 2006 and 2010 indicate that 52% of DVT patients and 90% of PE patients were managed in the hospital. A retrospective analysis of 639 patients with PE and DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among PE patients only.

In summary, observational studies continue to report in hospital management of DVT and PE. An analysis of 652,000 and 394,000 emergency room visits in the US for DVT and PE between 2006 and 2010 indicate that 52% of DVT patients and 90% of PE patients were managed in the hospital. A retrospective analysis of 639 patients with PE and DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among PE patients only.

In summary, observational studies continue to report in hospital management of DVT and PE. An analysis of 652,000 and 394,000 emergency room visits in the US for DVT and PE between 2006 and 2010 indicate that 52% of DVT patients and 90% of PE patients were managed in the hospital. A retrospective analysis of 639 patients with PE and DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among DVT and among all 4 outcomes for patients with PE was attributed mostly to very serious imprecision in the pooled estimates. Among PE patients only.
administration of other medications due to possible interactions. More recent clinical guidelines recommend the use of DOACs which require no subcutaneous injections or routine follow up for laboratory monitoring. Theoretically DOAC therapy should make it even easier for patients to be treated at home for DVT resulting in lower costs and less demand for hospital beds. An international multicenter single-arm RCT, published in 2019, investigated early discharge vs hospital treatment of patients with low-risk PE treated with rivaroxaban. This study did not fulfill the inclusion criteria in our review, given the single-arm study design. However, results from 525 patients included in planned interim analysis shows that only 3 patients (0.6%) suffered symptomatic non-fatal VTE recurrence. Major bleeding occurred in 6 of the 519 patients (1.2%) comprising the safety population suggesting that early discharge and home treatment with rivaroxaban is effective and safe in carefully selected patients with low-risk PE.30

Strengths and limitations of study

Our report has a few strengths. First, we conducted a comprehensive review of the literature that covers management of DVT as well as PE and that includes evidence from RCTs and observational cohort studies. The review included a systematic search of the literature and independent duplicate screening and data extraction. A second strength is the clinical expertise and methodology input from the ASH VTE treatment panel. Third, we clearly define home management as a short hospital admission for up to 72 hours after diagnosis and continued treatment at home past the 72 hours. Previous studies have not usually clarified this as an inclusion criterion. Previous reviews downgraded the quality of the evidence due to indirectness due to variability in defining home management. We excluded studies that reported a longer hospital stay for the intervention arm (home management). Therefore, our final quality of evidence assessment for this outcome was moderate, which will be related to more confidence in the effect estimates.

The small number of included studies, small number of patients in each group, and the very low to moderate certainty of included studies are limitations to this review. This was especially true for evidence regarding PE management, possibly due to low event rates associated with PE. Our search did not identify any new or ongoing RCTs to provide a clear answer for PE management at home. All but 1 of the studies included patients treated with VKA and/or LMWH, only 1 study included patients on DOACs. Due to the small number of studies with patients on DOACs subgroup analysis by type of anticoagulant was not possible. The 1 study that included patients on DOACs reported zero events, across all outcomes of interest, in both study groups. This is likely due to the small sample size in the study and the low event rate of these outcomes among patients treated with DOACs. Safety and efficacy are likely greater in DOACs compared with VKA and LMWH, suggesting that including more studies with patients on DOACs will likely show an increased benefit in home treatment of VTE.

Conclusion

Our findings indicate that DVT patients at low risk of complications had similar or lower risk of patient-important outcomes with home treatment compared with hospital treatment. In patients with low-risk PE, there was important uncertainty about a difference between home and hospital treatment.

Acknowledgments

This systematic review was performed as part of the American Society of Hematology (ASH) guidelines for VTE.

Authorship

Contribution: R.K. and Y.Z. contributed to study design, data extraction, statistical analysis, interpretation of results, and writing of the report; S.R., S.A.K., and I.D.F. contributed to study design, search strategy, study selection, data extraction, interpretation of results, and writing of the report; and T.L.O., R.N., I.N., D.M.W., S.S., V.M., R.B., N.P.C., W.W., and H.J.S. contributed to the study design, interpretation of the results, and writing of the report.

Conflict-of-interest disclosure: R.K. received research support from Bristol-Myers Squibb and Takeda. D.M.W received research support and consulting fees from Roche Diagnostics. H.J.S. was the principal investigator for the McMaster GRADE Centre and received funding from ASH that supported this systematic review. The remaining authors declare no competing financial interests.

ORCID profiles: I.D.F., 0000-0002-0751-8932; D.M.W., 0000-0002-3930-8358; V.M., 0000-0003-0410-8089; N.P.C., 0000-0002-9289-7710; W.W., 0000-0001-6576-1650; H.J.S., 0000-0003-3211-8479; Y.Z., 0000-0002-6318-3575.

Correspondence: Yuqing Zhang, Department of Health Research Methods, Evidence and Impact, McMaster University, 1280 Main St W, Hamilton, ON L8S 4L8, Canada; e-mail: madison1220@gmail.com or zhang363@mcmaster.ca.

References

1. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am J Med. 2013;126(9):832.e13-832.e21.
2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159(5):445-453.
3. McAfee SJ, Ginsberg JS. Initial treatment of venous thromboembolism [published corrections appear in Circulation. 2004;110(24 suppl 1):IV33 and Circulation. 2005;111(3):378]. Circulation. 2004;110(9 suppl 1):I3-I9.
4. Koopman MM, Prandoni P, Piovella F, et al; The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334(11):682-687.
5. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334(11):877-881.
6. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(suppl 2):e419S-e496S.

7. Kearon C, Akl EA, Omelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report [published correction appears in Chest. 2016;150(4):988]. Chest. 2016;149(2):315-352.

8. Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: a systematic review and meta-analyses. Clin Ther. 2017;39(7):1456-1478.e36.

9. Vinson DR, Ballard DW, Huang J, et al; MAPLE Investigators of the KP CREST Network. Outpatient management of emergency department patients with acute pulmonary embolism: variation, patient characteristics, and outcomes. Ann Emerg Med. 2018;72(1):62-72.e3.

10. Singer AJ, Thode HC Jr., Peacock WF IV. Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. Clin Exp Emerg Med. 2016;3(3):126-131.

11. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.handbook.cochrane.org. Accessed 10 October 2019.

12. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.

13. Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 2018;1:CD003076.

14. MDCalc. Pulmonary Embolism Severity Index (PESI). Available at: https://www.mdcalc.com/pulmonary-embolism-severity-index-pesi. Accessed 15 November 2019.

15. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antithromostatic medicinal products in non-surgical patients. J Thromb Haemost. 2003;3(4):692-694.

16. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-926.

17. Boccalon H, Elias A, Chalé JJ, Cadêne A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med. 2000;160(12):1769-1773.

18. Ramacciotti E, Araújo GR, Lastoria S, et al; CLETARAT Investigators. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res. 2004;114(3):149-153.

19. Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH; ASTH DVT Study Group. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis. 2005;19(3):173-181.

20. Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg. 2005;29(6):638-650.

21. Romera-Villegas A, Cairois-Castellote MA, Vila-Coll R, et al. Early mobilisation in patients with acute deep vein thrombosis does not increase the risk of a symptomatic pulmonary embolism. Int Angiol. 2008;27(6):494-499.

22. Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet. 2011;378(9785):41-48.

23. Frank Peacock W, Coleman CI, Diercks DB, et al. Emergency department discharge of pulmonary embolus patients. Acad Emerg Med. 2018;25(9):995-1003.

24. Beer JH, Burger M, Gretener S, Bernhard-Bagattini S, Bounaumeau H. Outpatient treatment of pulmonary embolism is feasible and safe in a substantial proportion of patients. J Thromb Haemost. 2003;1(1):186-187.

25. Siragusa S, Arcara C, Malato A, et al. Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients. Ann Oncol. 2005;16(suppl 4):iv136-iv139.

26. Rodriguez-Cerrillo M, Alvarez-Arcaya A, Fernández-Diaz E, Fernández-Cruz A. A prospective study of the management of non-massive pulmonary embolism in the home. Eur J Intern Med. 2009;20(6):598-600.

27. Kovacs MJ, Hawel JD, Rekan F, Lazo-Langer A. Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost. 2010; 8(11):2406-2411.

28. Kahler ZP, Beam DM, Kline JA. Cost of treating venous thromboembolism with heparin and warfarin versus home treatment with rivaroxaban. Acad Emerg Med. 2015;22(7):796-802.

29. Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated venous thromboembolism (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158-163.

30. Barco S, Schmidtmann I, Ageno W, et al; HoT-PE Investigators. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial [published online ahead of print 23 May 2019]. Eur Heart J. doi:10.1093/eurheartj/ehz367.

31. Yoo HH, Nunes-Nogueira VS, Fortes Villas Boas PJ, Broderick C. Outpatient versus inpatient treatment for acute pulmonary embolism. Cochrane Database Syst Rev. 2019;3:CD010019.

32. Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J. 2013;42(1):134-144.

33. Lozano F, Trujillo-Santos J, Barron M, et al. Home versus in-hospital treatment of patients with acute deep venous thrombosis of the lower limbs. J Vasc Surg. 2014;59(5):1362-1367.e1.